The number of confirmed Rifampicina Resistant/Multi-Drug Resistant Tuberculosis (RR-/MDR-TB) cases in India was 53.75 thousand in 2023. From 2024 to 2028, the cases are forecasted to rise annually, signaling an upward trend. The year-on-year growth rates from 2024 to 2028 show an average increase of approximately 3.15%. Over the five-year forecast period, the compound annual growth rate (CAGR) is expected to be around 3.18%.
Future trends to watch include:
- Impact of healthcare interventions and new drug therapies on MDR-TB case numbers.
- Potential policy changes to enhance TB control and resistance tracking.
- Influence of socio-economic factors on TB prevalence and resistance development.
